Article
Evolutionary biology of high-risk multiple myeloma.
Nature reviews. Cancer - 24 Aug 2017
Pawlyn Charlotte, Morgan Gareth J
Abstract excerpt
The outcomes for the majority of patients with myeloma have improved over recent decades, driven by treatment advances. However, there is a subset of patients considered to have high-risk disease who have not benefited. Understanding how high-risk disease evolves from more therapeutically tractable stages is crucial if we are to improve outcomes. This can be accomplished by identifying the genetic mechanisms and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
